Results 101 to 110 of about 2,469,529 (358)

Development of therapeutic antibodies for the treatment of diseases

Journal of Biomedical Sciences, 2020
It has been more than three decades since the first monoclonal antibody was approved by the United States Food and Drug Administration (US FDA) in 1986, and during this time, antibody engineering has dramatically evolved.
Ruei-Min Lu, Yu-Chyi Hwang, I. Liu, Chi-Chiu Lee, Han-zen Tsai, Hsin-Jung Li, Han‐Chung Wu   +6 more
semanticscholar   +1 more source

Escape from TGF‐β‐induced senescence promotes aggressive hallmarks in epithelial hepatocellular carcinoma cells

Molecular Oncology, EarlyView.
Chronic TGF‐β exposure drives epithelial HCC cells from a senescent state to a TGF‐β resistant mesenchymal phenotype. This transition is characterized by the loss of Smad3‐mediated signaling, escape from senescence, enhanced invasiveness and metastatic potential, and upregulation of key resistance modulators such as MARK1 and GRM8, ultimately promoting
Minenur Kalyoncu, Dilara Demirci, Sude Eris, Bengisu Dayanc, Ece Cakiroglu, Merve Basol, Merve Uysal, Gulcin Cakan‐Akdogan, Fang Liu, Mehmet Ozturk, Gökhan Karakülah, Serif Senturk   +11 more
wiley   +1 more source

Apolipoprotein E mediates evasion from hepatitis C virus−neutralizing antibodies [PDF]

, 2016
Background & Aims Efforts to develop an effective vaccine against hepatitis C virus (HCV) have been hindered by the propensity of the virus to evade host immune responses. HCV particles in serum and in cell culture associate with lipoproteins, which
Bartenschlager, Ralf, Baumert, Thomas F., Crouchet, Emilie, Fauvelle, Catherine, Felmlee, Daniel J., Fofana, Isabel, Foung, Steven K.H., Habersetzer, François, Heydmann, Laura, Hiet, Marie-Sophie, Lee, JiYoung, Lefèvre, Mathieu, Magri, Andrea, Meuleman, Philip, Milne, Ross, Patel, Arvind H., Schuster, Catherine, Vercauteren, Koen, Zeisel, Mirjam B.   +18 more
core   +3 more sources

Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy

Nature Communications, 2016
Cancer cells express tumour-specific antigens derived via genetic and epigenetic alterations, which may be targeted by T-cell-mediated immune responses.
Ju Yeon Lee, Hyun Tae Lee, Woori Shin, Jong-Kun Chae, Jaehyuk Choi, Sung Hyun Kim, Heejin Lim, Tae Won Heo, Kyeong Young Park, Yeon Ji Lee, S. Ryu, J. Son, Jee Un Lee, Y. Heo   +13 more
semanticscholar   +1 more source

Fragmentation of monoclonal antibodies [PDF]

mAbs, 2011
Fragmentation is a degradation pathway ubiquitously observed in proteins despite the remarkable stability of peptide bond; proteins differ only by how much and where cleavage occurs. The goal of this review is to summarize reports regarding the non-enzymatic fragmentation of the peptide backbone of monoclonal antibodies (mAbs).
Josef Vlasak, Roxana Ionescu
openaire   +3 more sources

Inhibitor of DNA binding‐1 is a key regulator of cancer cell vasculogenic mimicry

Molecular Oncology, EarlyView.
Elevated expression of transcriptional regulator inhibitor of DNA binding 1 (ID1) promoted cancer cell‐mediated vasculogenic mimicry (VM) through regulation of pro‐angiogenic and pro‐cancerous genes (e.g. VE‐cadherin (CDH5), TIE2, MMP9, DKK1). Higher ID1 expression also increased metastases to the lung and the liver.
Emma J. Thompson, Emma L. Dorward, Kristyn Jurrius, Nathalie Nataren, Markus Tondl, Kay K. Myo Min, Michaelia P. Cockshell, Anahita Fouladzadeh, John Toubia, Mark DeNichilo, Delphine Merino, Claudine S. Bonder   +11 more
wiley   +1 more source

Signaling dependent and independent mechanisms in pemphigus vulgaris blister formation. [PDF]

PLoS ONE, 2012
Pemphigus vulgaris (PV) is an autoimmune epidermal blistering disease caused by autoantibodies directed against the desmosomal cadherin desmoglein-3 (Dsg3). Significant advances in our understanding of pemphigus pathomechanisms have been derived from the
Masataka Saito, Sara N Stahley, Christopher Y Caughman, Xuming Mao, Dana K Tucker, Aimee S Payne, Masayuki Amagai, Andrew P Kowalczyk   +7 more
doaj   +1 more source

Structure and pathogenicity of antibodies specific for citrullinated collagen type II in experimental arthritis [PDF]

, 2009
Antibodies to citrulline-modifi ed proteins have a high diagnostic value in rheumatoid arthritis (RA). However, their biological role in disease development is still unclear.
Aho, Andersson, Auger, Baeten, Bella, Bettina Sehnert, Brunsberg, Burkhardt, Burkhardt, Bäcklund, Caspi, Chang, Chapuy-Regaud, Collaborative Computational Project, Number 4, DeLano, Dyson, Emsley, Emsley, Emsley, Estelle Bajtner, Foulquier, Girbal-Neuhauser, Giudicelli, Grab, Guy Serre, Harald Burkhardt, Hill, Hill, Hoffmann, Hüseyin Uysal, Kabsch, Kanazawa, Kidd, Krissinel, Kuhn, Kutty S. Nandakumar, Lefranc, Marjolein M.G.M. Thunnissen, Masson-Bessière, Masson-Bessière, Michaëlsson, Molberg, Murshudov, Nair, Nandakumar, Rantapää-Dahlqvist, Read, Reparon-Schuijt, Rikard Holmdahl, Robert Bockermann, Rosloniec, Schellekens, Schellekens, Schulte, Schwab, Stanfield, Stetefeld, Tarcsa, Uysal, van der Helm-van Mil, Vander Cruyssen, von Delwig, Vossenaar, Vossenaar, Vossenaar, Vossenaar, Winn, Yousfi Monod, Zong, Åke Engström   +69 more
core   +2 more sources

Tonic signaling of the B‐cell antigen‐specific receptor is a common functional hallmark in chronic lymphocytic leukemia cell phosphoproteomes at early disease stages

Molecular Oncology, EarlyView.
B‐cell chronic lymphocytic leukemia (B‐CLL) and monoclonal B‐cell lymphocytosis (MBL) show altered proteomes and phosphoproteomes, analyzed using mass spectrometry, protein microarrays, and western blotting. Identifying 2970 proteins and 316 phosphoproteins, including 55 novel phosphopeptides, we reveal BCR and NF‐kβ/STAT3 signaling in disease ...
Paula Díez, Pablo Juanes‐Velasco, Marina L. García‐Vaquero, Conrad Droste, Alicia Landeira‐Viñuela, Miguel Alcoceba, Helena Fidalgo‐Gómez, Sara Misiego‐Herrero, Almudena Navarro‐Bailón, Mónica Baile, José M. Bastida, Jose Manuel Sanchez‐Santos, Rafael Góngora, Julia Almeida, Marcos Gonzalez‐Diaz, Alberto Orfao, Javier De Las Rivas, Manuel Fuentes   +17 more
wiley   +1 more source

Monoclonal IgY antibodies: advancements and limitations for immunodiagnosis and immunotherapy applications

Therapeutic Advances in Vaccines and Immunotherapy
Due to their high specificity and scalability, Monoclonal IgY antibodies have emerged as a valuable alternative to traditional polyclonal IgY antibodies.
Ashraf A. Tabll, Yasser E. Shahein, Mohamed M. Omran, Nahla A. Hussein, Asmaa El-Shershaby, Ana Petrovic, Marija Glasnovic, Robert Smolic, Martina Smolic   +8 more
doaj   +1 more source